Antidiabetik Oral Kombinasi Penghambat DPP-4 dan Penghambat SGLT-2
DOI:
https://doi.org/10.55175/cdk.v48i12.157Keywords:
Diabetes melitus, DM, penghambat DPP-4,, penghambat SGLT-2, antidiabetikAbstract
Dalam tatalaksana diabetes melitus tipe 2, terapi kombinasi dua obat antidiabetik disarankan jika dengan monoterapi gagal mencapai target kontrol glikemik. Pemilihan jenis obat antidiabetik tergantung kondisi pasien dan profil obat. Kombinasi obat antidiabetik oral golongan penghambat DPP-4 (dipeptidyl peptidase-4) dan penghambat SGLT-2 (sodium-glucose cotransporter type 2) dapat menjadi salah satu pilihan.
Combination of two antidiabetic drugs is recommended in the management of type 2 diabetes mellitus if monotherapy fails to achieve glycemic control targets. Choice of antidiabetic drugs depends on the patient's condition and drugs’ profile. Combination of oral antidiabetic drugs DPP-4 (dipeptidyl peptidase-4) class and SGLT-2 (sodium-glucose cotransporter type 2) inhibitors can be an option.
Downloads
References
L Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26(1):107-39.
PERKENI. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia 2019. Jakarta: PERKENI; 2019.
Gu N, Park SI, Chung H, Jin X, Lee S, Kim TE. Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor. Transl Clin Pharmacol.2020;28(1):17-33.
Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95.
Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018;61:2461-98.
Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med.2020;383(15):1425-35.
Combining DPP-4 inhibitor, SGLT2 inhibitor for type 2 diabetes cost-effective over time, AJMC® Study Says [Internet]. 2021 [cited 2021 March 29]. Available from: https://www.ajmc.com/view/combining-dpp4-inhibitor-sglt2-inhibitor
Pawaskar M, Bilir SP, Kowal S, Gonzalez C, Rajpathak S, Davies G. Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes. Am J Manag Care. 2019;25(5):231-8.
QTERN [Internet]. 2019 [cited 2021 November 2]. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209091s002lbl.pdf
GLYXAMBI [Internet]. 2019 [cited 2021 November 2]. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206073s022lbl.pdf
STEGLUJAN [Internet]. 2017 [cited 2021 November 2]. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209805s000lbl.pdf
Tang H, Fang Z, Wang T, Cui W, Zhai S, Song Y. Meta-analysis of effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes and all-cause mortality among patients with type 2 diabetes mellitus. Am J Cardiol. 2016;118(11):1774-80.
Chambergo-Michilot D, Tauma-Arrué A, Loli-Guevara S. Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2020;32:100690.
Ling J, Cheng P, Ge L, Zhang DH, Shi AC, Tian JH, et al. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: A Bayesian network metaanalysis of 58 randomized controlled trials. Acta Diabetol. 2019;56(3):249-72.
Liu D, Jin B, Chen W, Yun P. Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): A systematic review and meta-analysis. BMC Pharmacol Toxicol. 2019;20(1):15.
Cho YK, Kang YM, Lee SE, Lee J, Park JY, Lee WJ, et al. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab. 2018;44(5):393-401.
Min SH, Yoon JH, Moon SJ, Hahn S, Cho YM. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: A systematic review with meta-analysis. Sci Rep. 2018;8(1):4466.
Li D, Shi W, Wang T, Tang H. SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2018;20(8):1972-6
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Cermin Dunia Kedokteran
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
